AuthorsLambert, J S
Else, L J
Back, D J
Connor, E O
Khoo, S H
AffiliationThe Rotunda Hospital, Dublin, Ireland.
Chromatography, High Pressure Liquid
Pregnancy Complications, Infectious
MetadataShow full item record
CitationTherapeutic drug monitoring of lopinavir/ritonavir in pregnancy. 2011, 12 (3):166-73 HIV Med.
AbstractThe aim of the study was to determine total and unbound lopinavir (LPV) plasma concentrations in HIV-infected pregnant women receiving lopinavir/ritonavir (LPV/r tablet) undergoing therapeutic drug monitoring (TDM) during pregnancy and postpartum.
Women were enrolled in the study who were receiving the LPV/r tablet as part of their routine prenatal care. Demographic and clinical data were collected and LPV plasma (total) and ultrafiltrate (unbound) concentrations were determined in the first, second and third trimesters using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Postpartum sampling was performed where applicable. Antepartum and postpartum trough concentrations (C(trough) ) were compared independently [using analysis of variance (anova)] and on a longitudinal basis (using a paired t-test).
Forty-six women were enrolled in the study (38 Black African). Forty women initiated LPV/r treatment in pregnancy. Median (range) gestation at initiation was 25 (15-36) weeks and median (range) baseline CD4 count and viral load were 346 (14-836) cells/μL and 8724 (<50-267408) HIV-1 RNA copies/mL, respectively. Forty women (87%) had LPV concentrations above the accepted minimum effective concentration for wild-type virus (MEC; 1000 ng/mL). Geometric mean (95% confidence interval [CI]) total LPV concentrations in the first/second [3525 (2823-4227) ng/mL; n=16] and third [3346 (2813-3880) ng/mL; n=43] trimesters were significantly lower relative to postpartum [5136 (3693-6579) ng/mL; n=12] (P=0.006). In a paired analysis (n=12), LPV concentrations were reduced in the third trimester [3657 (2851-4463) ng/mL] vs. postpartum (P=0.021). No significant differences were observed in the LPV fraction unbound (fu%). Conclusions The above target concentrations achieved in the majority of women and similarities in the fu% suggest standard dosing of the LPV/r tablet is appropriate during pregnancy. However, reduced LPV concentrations in the second/third trimesters and potentially compromised adherence highlight the need for TDM-guided dose adjustment in certain cases.
- Reduced lopinavir exposure during pregnancy.
- Authors: Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS
- Issue date: 2006 Oct 3
- Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
- Authors: Manavi K, McDonald A, Al-Sharqui A
- Issue date: 2007 Mar 12
- Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
- Authors: Rosso R, Di Biagio A, Dentone C, Gattinara GC, Martino AM, Viganò A, Merlo M, Giaquinto C, Rampon O, Bassetti M, Gatti G, Viscoli C
- Issue date: 2006 Jun
- Steady-state lopinavir levels in third trimester of pregnancy.
- Authors: Lyons F, Lechelt M, De Ruiter A
- Issue date: 2007 May 11
- Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
- Authors: Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M
- Issue date: 2008 Oct